Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Crespo

Showing results (331-340 of 366) with videos related to

Pageof 37
Sort By:
Gastroenterologia Y Hepatologia|June 23, 2018
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349]Rocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
United European Gastroenterology Journal|June 19, 2024
Fibroblast growth factor 21 is a hepatokine involved in MASLD progressionRocío Gallego-Durán, Javier Ampuero, Douglas Maya-Miles, et al.
Cell Metabolism|February 22, 2020
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride AssemblyJorge Simon, Maitane Nuñez-García, Pablo Fernández-Tussy, et al.
Cell Metabolism|February 24, 2026
Lack of PCK1 in hepatic stellate cells causes liver fibrosis by fueling tricarboxylic acid cycle and increasing glycolysisEva Novoa, Tamara Parracho, Julica Inderhees, et al.
The Lancet. Gastroenterology & Hepatology|March 26, 2026
Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysisZobair M Younossi, Aleksander Krag, Shira Zelber-Sagi, et al.
Molecular Metabolism|June 21, 2021
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axisMarina Serrano-Maciá, Jorge Simón, Maria J González-Rellan, et al.
Nature Reviews. Gastroenterology & Hepatology|October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statementJeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Journal of Hepatology|July 22, 2025
Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN studyÁngela Puente, Fanny Turón, Javier Martínez, et al.
Hepatology (Baltimore, Md.)|December 6, 2024
Modulatory effects of CNNM4 on protein- l -isoaspartyl- O -methyltransferase repair function during alcohol-induced hepatic damageIrene González-Recio, Naroa Goikoetxea-Usandizaga, Claudia M Rejano-Gordillo, et al.
Pageof 37

Showing results (331-340 of 366) with videos related to

Sort By:
Pageof 37
Gastroenterologia Y Hepatologia|June 23, 2018
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349]Rocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
United European Gastroenterology Journal|June 19, 2024
Fibroblast growth factor 21 is a hepatokine involved in MASLD progressionRocío Gallego-Durán, Javier Ampuero, Douglas Maya-Miles, et al.
Cell Metabolism|February 22, 2020
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride AssemblyJorge Simon, Maitane Nuñez-García, Pablo Fernández-Tussy, et al.
Cell Metabolism|February 24, 2026
Lack of PCK1 in hepatic stellate cells causes liver fibrosis by fueling tricarboxylic acid cycle and increasing glycolysisEva Novoa, Tamara Parracho, Julica Inderhees, et al.
The Lancet. Gastroenterology & Hepatology|March 26, 2026
Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysisZobair M Younossi, Aleksander Krag, Shira Zelber-Sagi, et al.
Molecular Metabolism|June 21, 2021
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axisMarina Serrano-Maciá, Jorge Simón, Maria J González-Rellan, et al.
Nature Reviews. Gastroenterology & Hepatology|October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statementJeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Journal of Hepatology|July 22, 2025
Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN studyÁngela Puente, Fanny Turón, Javier Martínez, et al.
Hepatology (Baltimore, Md.)|December 6, 2024
Modulatory effects of CNNM4 on protein- l -isoaspartyl- O -methyltransferase repair function during alcohol-induced hepatic damageIrene González-Recio, Naroa Goikoetxea-Usandizaga, Claudia M Rejano-Gordillo, et al.
Pageof 37